Additionally, in CRC, S100A4+ Mono and MT2A+ Macro showed persistently high TPGM and EPGM expression in advanced tumors and after treatment, suggesting novel prognostic and therapeutic avenues for patients with CRC (Figure 4D, Figure S1G). This evidence concerns the gene MT2A and colorectal carcinoma.